Abstract
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 243-249 |
| Number of pages | 7 |
| Journal | Clinical, Cosmetic and Investigational Dermatology |
| Volume | 7 |
| DOIs | |
| State | Published - Sep 2 2014 |
Fingerprint
Keywords
- Psoriasis
- Psoriatic arthritis
- Ustekinumab
ASJC Scopus subject areas
- Dermatology
Cite this
Ustekinumab for the treatment of psoriatic arthritis : An update. / Davari, Parastoo; Leo, Michael S.; Kamangar, Faranak; Fazel, Nasim.
In: Clinical, Cosmetic and Investigational Dermatology, Vol. 7, 02.09.2014, p. 243-249.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ustekinumab for the treatment of psoriatic arthritis
T2 - An update
AU - Davari, Parastoo
AU - Leo, Michael S.
AU - Kamangar, Faranak
AU - Fazel, Nasim
PY - 2014/9/2
Y1 - 2014/9/2
N2 - Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
AB - Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic arthritis. In this article, we review large-scale randomized clinical trials addressing the efficacy and safety profile of ustekinumab for the treatment of psoriatic arthritis.
KW - Psoriasis
KW - Psoriatic arthritis
KW - Ustekinumab
UR - http://www.scopus.com/inward/record.url?scp=84907879772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907879772&partnerID=8YFLogxK
U2 - 10.2147/CCID.S50003
DO - 10.2147/CCID.S50003
M3 - Article
VL - 7
SP - 243
EP - 249
JO - Clinical, Cosmetic and Investigational Dermatology
JF - Clinical, Cosmetic and Investigational Dermatology
SN - 1178-7015
ER -